Oscotec highlights anti-resistance cancer programs and ADEL-Y01 progress

Oscotec announced progress across its clinical pipeline, highlighting ADEL-Y01 and candidate compounds OCT-598 and P4899 aimed at overcoming next-generation anticancer treatment resistance.

The company did so at the “2025 Second Half R&D Day” held on Monday at the Federation of Korean Industries building in Yeouido, Seoul.

ADEL-Y01 is being developed with ADEL as an Alzheimer's treatment. It is in phase 1 clinical trials in the U.S. As a second-generation tau antibody, ADEL-Y01 has gained significant market interest, especially after UCB's proof-of-concept with bepranemab last November. The company is discussing technology transfer (licensing-out) with global pharmaceutical companies during phase 1.

The company also provided updates on the development progress of its next-generation pipeline, anti-resistance agents, explaining the mechanisms and research results for OCT-598, scheduled to enter clinical trials within the year, and the recently disclosed NUAK1/2 inhibitor, P4899.

Oscotec also presented an overview of its management strategy and upcoming initiatives.

CEO Yoon Tae-young said, “Since joining Oscotec in 2020, I have regularly shared R&D progress and achievements. My goal is to strengthen and diversify Oscotec's pipeline expertise. Oscotec's next-generation pipelines will gain global attention beyond the domestic market.”

Executive Vice President Shin Dong-jun said, “We aim to make Genosco a wholly owned subsidiary to improve governance and efficiency. By balancing short-term profitability with long-term innovation, we will create a roadmap and plans to enhance shareholder value.”

Detailed information regarding Oscotec's 2025 Second Half R&D Day event will be available later via video on the company's website.